Midafotel, formerly known as SDZ-EAA 494 and D-CPP-ene, is a potent, competitive antagonist at the NMDA receptor. It was originally designed as a potential therapy for excitotoxicity, epilepsy or neuropathic pain. It looked very promising in in vitro trials proving to be a potent competitive antagonist at the NMDA without affecting other receptors. References: Bespalov A, Kudryashova M, Zvartau E. Prolongation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene (SDZ EAA 494) in rats. Eur J Pharmacol. 1998 Jun 26;351(3):299-305. PubMed PMID: 9721021.

纯度：≥98%

CAS：117414-74-1